乌比昆醇对糖尿病前患者氧化低密度脂蛋白的影响:一项随机,双盲,安慰剂控制的随机研究
Romun Leaovitavat1, Pasita Palakornkitti1, Paphitchaya Thetsana2
1Anti-Aging and Regenerative Medicine, College of Integrative Medicine, Dhurakij Pundit University, Bangkok, Thailand, dpu.ac.th.
BioMed research international
|March 11, 2026
概括
在治疗组中的糖尿病前期患者中,乌比金补充剂显著降低了氧化低密度脂蛋白 (oxLDL). 这种抗氧化剂可能有助于管理患有禁食血葡萄糖受损的个体的心血管风险因素.
科学领域:
- 心血管研究研究心血管研究
- 营养生物化学 营养生物化学
- 代谢综合征是代谢综合征的一种.
背景情况:
- 氧化低密度脂蛋白 (oxLDL) 是氧化应激和心血管疾病风险的关键生物标志物.
- 前糖尿病是一种禁食血葡萄糖受损的状态,增加长期健康风险.
研究的目的:
- 研究乌比奎诺补充剂对糖尿病前期患者的oxLDL水平的影响.
- 评估ubiquinol作为一种干预措施来管理糖尿病前期患者的氧化负担的潜力.
主要方法:
- 一项前性,随机,双盲,安慰剂控制的试点研究.
- 20名患有禁食血葡萄糖受损的成年人每天接受100毫克乌比奎诺或安慰剂,持续12周.
- 血oxLDL水平在基线和12周后被测量.
主要成果:
- 与基线 (p=0.049) 相比,乌比奎诺尔组显示了血oxLDL的统计学显著降低.
- 在安慰剂组中没有观察到oxLDL的显著变化 (p=0.237).
- 在研究期间没有报告任何不良事件.
结论:
- 在12周内每天服用 (100毫克/天) 乌比奎诺,使得糖尿病前期参与者血LDL氧化物显著下降.
- 与安慰剂相比,oxLDL减少的组间差异没有达到统计学意义.
- 乌比金似乎是安全的,并可能为糖尿病前期患者的oxLDL管理提供好处.
相关概念视频
Oxidation of Phenols to Quinones
5.0K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
5.0K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management
541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
342
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
342
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
260
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
260
Coronary Artery Disease IV: Preventive Measures
790
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790


